Peanut allergy (PA) is a severe form of food allergy for which Improved treatments are needed. However, few Studies have been conducted to optimize the safety of oral immunotherapy (OIT) for PA, to tailor OIT protocols according to the needs of individual PA patients, or to identify the immunological mechanism(s) underlying any long-lasting effects of oral immunotherapy (OIT) in such subjects. Specifically, It is not yet clear what factors will determine, in individual subjects, whether OIT induces tolerance (in which no set dally use of that food alleroen is needed to allow for its safe consumption). To address these challenges, the Stanford Alliance for Food Allergy Research (SAFAR) plans to link the findings of the Phase 2 clinical study proposed here in Project 1 with the results of each of the other 3 projects of the U19 proposal focused on mechanistic studies (Projects 2, 3 &4), as well as with the results ofthe immune metrics assays carried out by Scientific Core B. Each of these projects and Core B will use patient samples from Project 1 collected at screening and longitudinally throughout the clinical study to Integrate all data. We propose 3 main goals of our research for Project 1:
Specific Aim 1 : Test whether treatment of PA patients with OIT allows tolerance to be achieved (i.e., allows the subject to stop maintenance ingestion of peanut [during an "avoidance period"] for 3 months or more but then still undergo a successful double-blind placebo-controlled food challenge [DBPCFC] with peanut).
Specific Aim 2 : Determine whether treatment with our OIT protocol is safe in children and adults with peanut allergy (PA).
Specific Aim 3 : Evaluate to what degree current laboratory and clinical testing methods are associated with safety and tolerance outcomes (as identified in Specific Aims 1 and 2) in subjects with PA. By pursuing these aims, we will both: 1) provide the clinical samples, and the clinical outcome data, that will permit the innovative immune monitoring and mechanistic studies proposed in this U19 application to be accomplished, and 2) determine whether performing such immune monitoring has the potential to permit Individualization and optimization of safe and efficacious OIT protocols for individual PA patients.

Public Health Relevance

Food allergy is an important disease of children and adults that is in need of improved therapy. We propose a Study to test whether adult and pediatric patients with one of the most dangerous food allergies, peanut allergy, can become tolerant to peanuts after an oral immunotherapy regimen so that they may be able to eat peanut safely.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI104209-01
Application #
8468483
Study Section
Special Emphasis Panel (ZAI1-PA-I (J1))
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
1
Fiscal Year
2013
Total Cost
$158,694
Indirect Cost
$57,615
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Syed, Aleena; Garcia, Marco A; Lyu, Shu-Chen et al. (2014) Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol 133:500-10
Galli, Stephen J (2014) Rethinking the potential roles of mast cells in skin wound healing and bleomycin-induced skin fibrosis. J Invest Dermatol 134:1802-4
Manohar, Monali; Nadeau, Kari C (2014) The Potential of Anti-IgE in Food Allergy Therapy. Curr Treat Options Allergy 1:145-156
Starkl, Philipp; Marichal, Thomas; Galli, Stephen J (2013) PLA2G3 promotes mast cell maturation and function. Nat Immunol 14:527-9